Clinical Trial for Cystic Fibrosis Patients
Celtaxsys is currently conducting a clinical trial testing the ability of oral once-daily acebilustat to help maintain lung function in adult patients over the course of 48 weeks.
NCT02443688 – Phase 2 Cystic Fibrosis – Ongoing (Fully Enrolled)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of acebilustat Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis.
Find out more about this trial – http://clinicaltrials.gov/show/NCT02443688.